{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:45:27Z","timestamp":1782665127298,"version":"3.54.5"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ck0106131"],"award-info":[{"award-number":["JP16ck0106131"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ck0106858"],"award-info":[{"award-number":["JP23ck0106858"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18ck0106335"],"award-info":[{"award-number":["JP18ck0106335"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ck0106613"],"award-info":[{"award-number":["JP21ck0106613"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["National Cancer Center Research and Development Fund"],"award-info":[{"award-number":["National Cancer Center Research and Development Fund"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109386","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:14:39Z","timestamp":1774545279000},"page":"109386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Five-year overall survival in JCOG1205\/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-9259","authenticated-orcid":false,"given":"Hirotsugu","family":"Kenmotsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-5923","authenticated-orcid":false,"given":"Seiji","family":"Niho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genichiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-3153","authenticated-orcid":false,"given":"Hajime","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-5901","authenticated-orcid":false,"given":"Kana","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriyuki","family":"Kiyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takekazu","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-4491","authenticated-orcid":false,"given":"Yoshiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyofumi Fengshi","family":"Chen-Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-7472","authenticated-orcid":false,"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1252-9935","authenticated-orcid":false,"given":"Wataru","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-5010","authenticated-orcid":false,"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Mitome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Asamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6137-073X","authenticated-orcid":false,"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1927-9675","authenticated-orcid":false,"given":"Shun-ichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109386_b0005","series-title":"WHO Classification of Tumours of the Lung, Plueura, Thymus and Heart","first-page":"9","article-title":"Tumours of the lung","author":"Travis","year":"2015"},{"key":"10.1016\/j.lungcan.2026.109386_b0010","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"24 Suppl 6","author":"Fruh","year":"2013","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109386_b0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jjco\/hyt233","article-title":"A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205\/1206)","volume":"44","author":"Eba","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.lungcan.2026.109386_b0020","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.20.01806","article-title":"Randomized phase III study of irinotecan plus cisplatin versus etoposide plus cisplatin for completely resected high-grade neuroendocrine carcinoma of the lung: JCOG1205\/1206","volume":"38","author":"Kenmotsu","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109386_b0025","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10308","key":"10.1016\/j.lungcan.2026.109386_b0030","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109386_b0035","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109386_b0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.04.1202","article-title":"Neuroendocrine neoplasms of the lung: a prognostic spectrum","volume":"24","author":"Asamura","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109386_b0045","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jtcvs.2004.05.030","article-title":"Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the japan clinical oncology lung cancer study group trial (JCOG9101)","volume":"129","author":"Tsuchiya","year":"2005","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109386_b0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00000421-199304000-00001","article-title":"A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer","volume":"16","author":"Davis","year":"1993","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109386_b0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.lungcan.2014.03.007","article-title":"A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer)","volume":"84","author":"Kenmotsu","year":"2014","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109386_b0060","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jtho.2021.05.020","article-title":"Clinical-pathologic challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice","volume":"16","author":"Derks","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109386_b0065","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00000478-199808000-00003","article-title":"Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid","volume":"22","author":"Travis","year":"1998","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109386_b0070","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2559.2010.03486.x","article-title":"Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability","volume":"56","author":"den Bakker","year":"2010","journal-title":"Histopathology"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:22:58Z","timestamp":1782663778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":14,"alternative-id":["S0169500226004472"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109386","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year overall survival in JCOG1205\/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109386"}}